MoonLake Immunotherapeutics Overview
MoonLake Immunotherapeutics Target Price
Analysts' 12-month price predictions for MLTX.
Get informed when a big investor buys or sells
+ FollowShare Price
$18.72
Average Target Price
$40.00
113.7% upside
113.7% upside2 analysts in the last 4 months
High: $45 | Low: $35
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-05-11 | H.C. Wainwright | $45 | 140.4% upside |  |
| 2026-02-24 | Oppenheimer | $35 | 87% upside | |
| 2026-01-14 | Goldman Sachs | $10 |  46.6% downside | |
| 2026-01-09 | H.C. Wainwright | $32 | 70.9% upside | |
| 2026-01-09 | UBS | $24 | 28.2% upside | |
| 2026-01-08 | UBS | $45 | 140.4% upside | |
| 2025-11-21 | H.C. Wainwright | $26 | 38.9% upside | |
| 2025-11-06 | Oppenheimer | $30 | 60.3% upside | |
| 2025-11-03 | H.C. WainwrightRaghuram Selvaraju | $30 | 60.3% upside | |
| 2025-10-07 | Oppenheimer | $25 | 33.5% upside | |
| 2025-09-30 | Goldman Sachs | $7 | 62.6% downside | |
| 2025-09-30 | NeedhamSerge Belanger | $20 | 6.8% upside | |
| 2025-09-30 | Guggenheim | $20 | 6.8% upside | |
| 2025-09-29 | Jefferies | $8 | 57.3% downside | |
| 2025-09-29 | RBC Capital | $10 | 46.6% downside | |
| 2025-03-18 | RBC Capital | $67 | 257.9% upside | |
| 2024-07-01 | H.C. WainwrightRaghuram Selvaraju | $100 | 434.2% upside | |
| 2024-04-02 | Goldman SachsRichard Law | $62 | 231.2% upside | |
| 2023-08-31 | NeedhamSerge Belanger | $76 | 306% upside | |